Open AccessAntioxidant Therapy in Neurologic Disease
Author(s) -
Norman Delanty,
Marc A. Dichter
Publication year - 2000
Publication title -
archives of neurology
Language(s) - Uncategorized
Resource type - Journals
eISSN - 1538-3687
pISSN - 0003-9942
DOI - 10.1001/archneur.57.9.1265
Subject(s) - medicine , clinical trial , disease , ebselen , antioxidant , intensive care medicine , vitamin e , mechanism (biology) , pharmacology , bioinformatics , oxidative stress , pathology , chemistry , biology , biochemistry , catalase , philosophy , epistemology , glutathione peroxidase
Free radical or oxidative injury may be a fundamental mechanism underlying a number of human neurologic diseases. Therapy using free radical scavengers (antioxidants) has the potential to prevent, delay, or ameliorate many neurologic disorders. However, the biochemistry of oxidative pathobiology is complex, and optimum antioxidant therapeutic options may vary and need to be tailored to individual diseases. In vitro and animal model studies support the potential beneficial role of various antioxidant compounds in neurologic disease. However, the results of clinical trials using various antioxidants, including vitamin E, tirilazad, N-acetylcysteine, and ebselen, have been mixed. Potential reasons for these mixed results include lack of pretrial dose-finding studies and failure to appreciate and characterize the individual unique oxidative processes occurring in different diseases. Moreover, therapy with antioxidants may need to be given early in chronic insidious neurologic disorders to achieve an appreciable clinical benefit. Predisease screening and intervention in at-risk individuals may also need to be considered in the near future.